Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 294

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Prof Paul Richardson speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the updated results of the HORIZON trial.

Preliminary results were presented at the meeting regarding the efficacy and safety of melflufen in relapsed and refractory multiple myeloma patients refractory to daratumumab and/or pomalidomide.

Prof Richardson explains that melflufen continues to have promising results and was generally well tolerated, providing a valuable treatment option for particular subsets of patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 
 

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation